Recombinant antibodies for cancer diagnosis and therapy

Expert Opinion on Biological Therapy

Volumn 3, Issue 2, 2003, Pages 305-318

  Souriau, Christelle ^a   Hudson, Peter J ^a  

^a CSIRO   (Australia)

Author keywords

Antibodies; Bispecific; Cancer; Diabodies; Diagnosis; Fab; Immunotoxin; Library selection; Radiolabelling; scFv

Indexed keywords

ALEMTUZUMAB; ASTATINE 211; BIOTIN; BISMUTH 213; CELL SURFACE PROTEIN; CHELATE; EDRECOLOMAB; FLUORINE 18; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IODINE 123; RADIOISOTOPE; RECOMBINANT ANTIBODY; RITUXIMAB; STREPTAVIDIN; TRASTUZUMAB; TUMOR ANTIGEN;

ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY ENGINEERING; ANTIBODY LIBRARY; ANTIBODY SPECIFICITY; BREAST CARCINOMA; CANCER CELL DESTRUCTION; CANCER DIAGNOSIS; CARCINOMA; CLINICAL TRIAL; COLON CARCINOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; FOOD AND DRUG ADMINISTRATION; HUMAN; IMAGE ENHANCEMENT; ISOTOPE LABELING; LEUKEMIA; LYMPHOMA; NONHUMAN; PHARMACEUTICAL ENGINEERING; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIOIMMUNOTHERAPY; REVIEW; SOLID TUMOR; TREATMENT INDICATION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOLOGIC TESTS; NEOPLASMS; RADIOIMMUNOTHERAPY; RECOMBINANT PROTEINS;

EID: 0037391745     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.2.305     Document Type: Review

References (150)

1. MILSTEIN C: With the benefit of hindsight. Immunol Today (2000) 21:359-364.
2. WISEMAN GA, LEIGH B, ERWIN WD et al.: Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer (2002) 94:1349-1357.
3. CARTER P: Improving of the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer (2001) 1:118-129. A review on antibody designs for enhancing cancer immunotherapy.
4. HUDSON PJ, SOURIAU C: Engineered antibodies. Nat. Med. (2003) 9:129-134.
5. BORREBAECK CA, CARLSSON R: Human therapeutic antibodies. Curr. Opin. Pharmacol. (2001) 1:404-408.
6. YOKOTA T, MILENIC DE, WHITLOW M, SCHLOM J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. (1992) 52:3402-3408.
7. KIM DJ, CHUNG JH, RYU YS et al.: Production and characterisation of a recombinant scFv reactive with human gastrointestinal carcinomas. Br. J. Cancer (2002) 87:405-413.
8. BIRD RE, HARDMAN KD, JACOBSON JW et al.: Single-chain antigen-binding proteins. Science (1988) 242:423-426.
9. HENDERIKX P, COOLEN-VAN NEER N, JACOBS A et al.: A human immunoglobulin G-antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized. Am. J. Pathol. (2002) 160:1597-1608.
10. MARTARELLO L, MCCONATHY J, CAMP VM et al.: Synthesis of syn- and anti-1-amino-3-[18F]fluoromethyl-cyclobutane-1-carboxylic acid (FMACBC), potential PET ligands for tumor detection. J. Med. Chem. (2002) 45:2250-2259.
11. CASEY JL, NAPIER MP, KING DJ et al.: Tumour targeting of humanised cross-linked divalent-Fab'antibody fragments: a clinical Phase I/II study. Br. J. Cancer (2002) 86:1401-1410.
12. KORTT AA, DOLEZAL O, POWER BE, HUDSON PJ: Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. (2001) 18:95-108.
13. GROULET A, DORVILLIUS M, PELEGRIN A, BARBET J, BATY D: Pharmacokinetic and tumor-seeking properties of recombinant and nonrecombinant anti-carcinoembryonic antigen antibody fragments. Int. J. Cancer (2002) 100:367-374.
14. GOEL A, BARANOWSKA-KORTYLEWICZ J, HINRICHS SH et al.: 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma. J. Nucl. Med (2001) 42:1519-1527.
15. LEE YC, BOEHM MK, CHESTER KA, BEGENT RH, PERKINS SJ: Reversible dimer formation and stability of the anti-rumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy. J. Mol. Biol. (2002) 320:107-127.
16. WU AM, TAN GJ, SHERMAN MA et al.: Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng. (2001) 14:1025-1033.
17. YAZAKI PJ, SHIVELY L, CLARK C et al.: Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. J. Immunol. Methods (2001) 253:195-208.
18. ARNDT KM, MULLER KM, PLUCKTHUN A: Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain. J. Mol. Biol. (2001) 312:221-228.
19. GURA T: Therapeutic antibodies: magic bullets hit the target. Nature (2002) 417:584-586.
20. IZUMI Y, XU L, DI TOMASO E, FUKUMURA D, JAIN RK: Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 416:279-280.
21. CARDARELLI PM, QUINN M, BUCKMAN D et al.: Binding to CD20 by anti-B1 antibody or F(ab′)(2) is sufficient for induction of apoptosis in B-cell fines. Cancer Immunol. Immunother. (2002) 51:15-24.
22. GOLDENBERG DM: Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. (2002) 43:693-713.
23. FLYNN AA, GREEN AJ, PEDLEY RB et al.: A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. Cancer (2002) 94:1249-1257.
24. LEWIS LD, BEELEN AP, COLE BF et al.: The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose Phase I study in patients with advanced cancer. Cancer Chemother. Pharmacol. (2002) 49:375-384.
25. RUNYON K, LEE K, ZUBEREK K, COLLINS M, LEONARD JP, DUNUSSI-JOANNOPOULOS K: The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses. Blood (2001) 97:2420-2426.
26. JUWEID ME: Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J. Nucl. Med. (2002) 43:1507-1529.
27. FLYNN AA, PEDLEY RB, GREEN AJ, BOXER GM, BODEN R, BEGENT RH: Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images. Cancer Biother. Radiopharm. (2001) 16:391-400.
28. WITZIG TE: Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Cancer Chemother. Pharmacol. (2001) 48(Suppl. 1):S91-S95.
29. KENNEL SJ, MIRZADEH S, ECKELMAN WC et al.: Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At. Radiat. Res. (2002) 157:633-641.
30. SGOUROS G, BALLANGRUD AM, JURCIC JG et al.: Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J. Nucl. Med. (1999) 40:1935-1946.
31. FLYNN AA, PEDLEY RB, GREEN AJ et al.: Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of rumour. Int. J. Radiat. Biol. (2002) 78:407-415.
32. MATSUMURA H, OTSUJI E, KOBAYASHI S, OKAMOTO K, TOMA A, YAMAGISHI H: Potential usefulness of 99mTc-labeled monoclonal antibody A7 for immunoscintigraphy of human pancreatic carcinoma. Anticancer Res. (2001) 21:3433-3437.
33. MILENIC DE, GARMESTANI K, CHAPPELL LL et al.: In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl. Med. Biol. (2002) 29:431-442.
34. NOVAK-HOFER I, SCHUBIGER PA: Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur. J. Nucl. Med Mol. Imaging (2002) 29:821-830.
35. LI L, OLAFSEN T, ANDERSON AL, WU A, RAUBITSCHEK AA, SHIVELY JE: Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. Bioconjug. Chem. (2002) 13:985-995.
36. WILLIAMS LE, WU AM, YAZAKI PJ et al.: Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother. Radiopharm. (2001) 16:25-35.
37. KIM MK, JEONG HJ, KAO CH et al.: Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications. Nucl. Med. Biol. (2002) 29:139-146.
38. GRANA C, CHINOL M, ROBERTSON C et al.: Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. J. Cancer (2002) 86:207-212.
39. SCHUHMACHER J, KLIVENYI G, KAUL S et al.: Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. Nucl. Med. Biol. (2001) 28:821-828.
40. YAO Z, ZHANG M, AXWORTHY DB et al.: Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N',N',-tetraacetic acid (DOTA)-biotin. Cancer Res. (2002) 62:5755-5760.
41. KRIANGKUM J, XU B, NAGATA LP, FULTON RE, SURESH MR: Bispecific and bifunctional single chain recombinant antibodies. Biomol. Eng. (2001) 18:31-40.
42. DMITRIEV DA, MASSINO YS, SEGAL OL et al.: Analysis of the binding of bispecific monoclonal antibodies with immobilized antigens (human IgG and horseradish peroxidase) using a resonant mirror biosensor. J. Immunol. Methods (2002) 261:103-118.
43. DENARDO DG, XIONG CY, SHI XB, DENARDO GL, DENARDO SJ: Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother. Radiopharm. (2001) 16:525-535.
44. LU D, JIMENEZ X, ZHANG H, BOHLEN P, WITTE L, ZHU Z: Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments. J. Immunol. Methods (2002) 267:213-226.
45. HILLAIRET DE BOISFERON M, RAGUIN O, THIERCELIN C et al.: Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model. Bioconjug. Chem. (2002) 13:654-662.
46. XIAO Z, MCQUARRIE SA, SURESH MR, MERCER JR, GUPTA S, MILLER GG: A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro. J. Biotechnol. (2002) 94:171-184.
47. XIONG D, XU Y, LIU H et al.: Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody. Cancer Lett. (2002) 177:29-39.
48. TAKEMURA S, KUDO T, ASANO R et al.: A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol. Immunother. (2002) 51:33-44.
49. WUEST T, MOOSMAYER D, PFIZENMAIER K: Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein. J Biotechnol. (2001) 92:159-168.
50. LU D, JIMENEZ X, ZHANG H et al.: Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res. (2001) 61:7002-7008. A novel and efficient bispecific antibody strategy, including designs for inhibition of angiogenesis via receptor blockade.
51. BALAIAN L, BALL ED: Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells. Leuk. Res. (2001) 25:1115-1125.
52. RUF P, LINDHOFER H: Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood (2001) 98:2526-2534. This article demonstrates the importance of the Fc region for immunotherapy.
53. KIPRIYANOV SM, COCHLOVIUS B, SCHAFER HJ et al.: Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J. Immunol. (2002) 169:137-144.
54. ZEIDLER R, MAYER A, GIRES O et al.: TNFalpha contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res. (2001) 21:3499-3503.
55. KODAMA H, SUZUKI M, KATAYOSE Y et al.: Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies. Immunol. Lett. (2002) 81:99-106.
56. VAN BEUSECHEM VW, GRILL J, MASTENBROEK DC et al.: Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J. Virol. (2002) 76:2753-2762.
57. MA Z, MI Z, WILSON A et al.: Redirecting adenovirus to pulmonary endothelium by cationic liposomes. Gene Ther. (2002) 9:176-182.
58. EZZELL C: Magic bullets fly again. Sci. Am. (2001) 285:34-41.
59. GARNETT MC: Targeted drug conjugates: principles and progress. Adv. Drug Deliv. Rev. (2001) 53:171-216.
60. ROSS S, SPENCER SD, HOLCOMB I et al.: Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. (2002) 62:2546-2553.
61. BRINKMANN U, KEPPLER-HAFKEMEYER A, HAFKEMEYER P: Recombinant immunotoxins for cancer therapy. Expert Opin. Biol. Ther. (2001) 1:693-702.
62. KOUSPAROU CA, EPENETOS AA, DEONARAIN MP: Antibody-guided enzyme therapy of cancer producing cyanide results in necrosis of targeted cells. Int. J. Cancer(2002) 99:138-148.
63. KHARE PD, LIAO S, HIROSE Y et al.: Tumor growth suppression by a retroviral vector displaying scFv antibody to CEA and carrying the iNOS gene. Anticancer Res. (2002) 22:2443-2446.
64. TANG Y, LI Y, QIAN G: Tumor cell-specific gene transfer with retroviral vectors displaying single-chain antibody. Chin. Med. J. (Engl.) (2002) 115:1064-1069.
65. JIN N, CHEN W, BLAZAR BR, RAMAKRISHNAN S, VALLERA DA: Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor-immunotoxin target gene. Hum. Gene Ther. (2002) 13:497-508.
66. HUSTON JS, GEORGE AJ: Engineered antibodies take center stage. Hum. Antibodies (2001) 10:127-142.
67. MODI S, SEIDMAN AD: An update on epidermal growth factor receptor inhibitors. Curr. Oncol. Rep. (2002) 4:47-55.
68. HARRINGTON KJ, MUBASHAR M, PETERS AM: Polyethylene glycol in the design of tumor-targetting radiolabelled macromolecules - lessons from liposomes and monoclonal antibodies. Q. J. Nucl. Med. (2002) 46:171-180.
69. NAGATA S, ONDA M, NUMATA Y et al.: Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin. Cancer Res. (2002) 8:2345-2355.
70. KREITMAN RJ: Toxin-labeled monoclonal antibodies. Curr. Pharm. Biotechnol. (2001) 2:313-325.
71. KREITMAN RJ: Chimeric fusion proteins-Pseudomonas exotoxin-based. Curr. Opin. Investig. Drugs (2001) 2:1282-1293.
72. FRANKEL AE: Increased sophistication of immunotoxins. Clin. Cancer Res. (2002) 8:942-944.
73. NIV R, ASSARAF YG, SEGAL D, PIRAK E, REITER Y: Targeting multidrug resistant tumor cell with a recombinant single-chain FV fragment directed to P-glycoprotein. Int. J. Cancer (2001) 94:864-872.
74. PEIPP M, KUPERS H, SAUL D et al.: A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. (2002) 62:2848-2855.
75. KODAMA H, SUZUKI M, KATAYOSE Y et al.: Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma. Cancer Immunol. Immunother. (2001) 50:539-548.
76. TUR MK, SASSE S, STOCKER M et al.: An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines. Int. J. Mol. Med. (2001) 8:579-584.
77. UENO A, ARAKAWA F, ABE H et al.: T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Anticancer Res. (2002) 22:769-776.
78. NG PP, DELA CRUZ JS, SOROUR DN et al.: An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc. Nat. Acad. Sci. USA (2002) 99:10706-10711. An excellent demonstration of the potency of antibody-avidin fusions to induce apoptosis.
79. HUHN M, SASSE S, TUR MK et al.: Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res. (2001) 61:8737-8742.
80. GRUEL N, FRIDMAN WH, TEILLAUD JL: Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-FcgammaR scFv on cancer cell surface. Gene Ther. (2001) 8:1721-1728. An innovative strategy fusing an scFv to a receptor transmembrane domain, leading to induction of phagocytosis. A promising new approach.
81. SHI N, BOADO RJ, PARDRIDGE WM: Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. (2001) 18:1091-1095.
82. WU D, SONG BW, VINTERS HV, PARDRIDGE WM: Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J. Drug Target. (2002) 10:239-245.
83. SHABAT D, LODE HN, PERTL U et al.: In vivo activity in a catalytic antibody-prodrug system: antibody catalyzed etoposide prodrug activarion for selective chemotherapy. Proc. Nat. Acad. Sci. USA (2001) 98:7528-7533.
84. WUEST T, GERLACH E, BANERJEE D, GERSPACH J, MOOSMAYER D, PFIZENMAIER K: TNF-selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor. Oncogene (2002) 21:4257-4265.
85. SUZAWA T, NAGAMURA S, SAITO H et al.: Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker. J. Control Release (2002) 79:229-242.
86. METELITSA LS, GILLIES SD, SUPER M, SHIMADA H, REYNOLDS CP, SEEGER RC: Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood (2002) 99:4166-4173.
87. RUEHLMANN JM, XIANG R, NIETHAMMER AG et al.: MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. (2001) 61:8498-8503.
88. STRUBE RW, CHEN SY: Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-F(c) intrabodies. J. Immunol. Methods (2002) 263:149-167.
89. VISINTIN M, SETTANNI G, MARITAN A, GRAZIOSI S, MARKS JD, CATTANEO A: The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J. Mol. Biol. (2002) 317:73-83.
90. LUNDE E, WESTERN KH, RASMUSSEN IB, SANDLIE I, BOGEN B: Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies. J. Immunol. (2002) 168:2154-2162.
91. WIRTH S, BILLE F, KOENIG S et al.: Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen. Int. J. Cancer (2002) 99:201-206.
92. ALVAREZ-VALLINA L: Genetic approaches for antigen-selective cell therapy. Curr. Gene Ther. (2001) 1:385-397.
93. HOMBACH A, HEUSER C, ABKEN H: The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr. Gene Ther. (2002) 2:211-226.
94. SONDEL PM, HANK JA: Antibody-directed, effector cell-mediated tumor destruction. Hematol. Oncol. Clin. N. Am. (2001) 15:703-721.
95. HANSEN HP, MATTHEY B, BARTH S et al.: Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. Int. J. Cancer (2002) 98:210-215.
96. FUJIOKA Y, ARANO Y, ONO M et al.: Renal metabolism of 3′-iodohippuryl N(epsilon)-maleoyi-L-lysine (HML)- conjugated Fab fragments. Bioconjug. Chem. (2001) 12:178-185.
97. AHONEN C, MANNING E, ERICKSON LD et al.: The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat. Immunol. (2002) 3:451-456.
98. AMSTUTZ P, FORRER P, ZAHND C, PLUCKTHUN A: In vitro display technologies: novel developments and applications. Curr. Opin. Biotechnol. (2001) 12:400-405.
99. HOOGENBOOM HR: Overview of antibody phage-display technology and its applications. Methods Mol. Biol. (2002) 178:1-37. This article provides a thorough and up-to-date review of the applications, opportunities and limitations of phage display technology.
100. SANZ L, KRISTENSEN P, BLANCO B et al.: Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther. (2002) 9:1049-1053.
101. SBLATTERO D, LOU J, MARZARI R, BRADBURY A: In vivo recombination as a tool to generate molecular diversity in phage antibody libraries. J. Biotechnol. (2001) 74:303-315.
102. O'CONNELL D, BECERRIL B, ROYBURMAN A, DAWS M, MARKS JD: Phage versus phagemid libraries for generation of human monoclonal antibodies. J. Mol. Biol. (2002) 321:49-56.
103. CHAMES P, HOOGENBOOM HR, HENDERIKX P: Selection of antibodies against biotinylated antigens. Methods Mol. Biol. (2002) 178:147-157.
104. DENKBERG G, COHEN CJ, LEV A, CHAMES P, HOOGENBOOM HR, REITER Y: Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc. Nat. Acad. Sci. USA (2002) 99:9421-9426.
105. SCHEFFER GL, REURS AW, JUTTEN B et al.: Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault protein. Br. J. Cancer (2002) 86:954-962.
106. BROCKS B, GARIN-CHESA P, BEHRLE E et al.: Species-crossreactive scFv against the tumor stroma marker fibroblast activation protein' selected by phage display from an immunized FAP-/-knock-out mouse. Mol. Med. (2001) 7:461-469.
107. TSE E, LOBATO MN, FORSTER A, TANAKA T, CHUNG GT, RABBITTS TH: Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J. Mol. Biol. (2002) 317:85-94.
108. DE WILDT RM, TOMLINSON IM, ONG JL, HOLLIGER P: Isolation of receptor-ligand pairs by capture of long-lived multivalent interaction complexes. Proc. Nat. Acad. Sci. USA (2002) 99:8530-8535.
109. LIU B, HUANG L, SIHLBOM C, BURLINGAME A, MARKS JD: Towards proteome-wide production of monoclonal antibody by phage display. J. Mol. Biol. (2002) 315:1063-1073.
110. AMSTUTZ P, PELLETIER JN, GUGGISBERG A et al.: In vitro selection for catalytic activity with ribosome display. J. Am. Chem. Soc. (2002) 124:9396-9403.
111. VAN DIJK MA, VAN DE WINKEL JG: Human antibodies as next generation therapeutics. Curr. Opin. Chem. Biol. (2001) 5:368-374.
112. ZHOU JM, FUJITA S, WARASHINA M, BABA T, TAIRA K: A novel strategy by the action of ricin that connects phenotype and genotype without loss of the diversity of libraries. J. Am. Chem. Soc. (2002) 124:538-543.
113. LAMLA T, MAMMERI K, ERDMANN VA: The cell-free protein biosynthesis-applications and analysis of the system. Acta Biochim. Pol. (2001) 48:453-465.
114. TAKAHASHI F, EBIHARA T, MIE M et al.: Ribosome display for selection of active dihydrofolate reductase mutants using immobilized methotrexate on agarose beads. FEBS Lett. (2002) 514:106-110.
115. JERMUTUS L, KOLLY R, FOLDESPAPP Z, HANES J, RIGLER R, PLUCKTHUN A: Ligand binding of a ribosome-displayed protein detected in solution at the single molecule level by fluorescence correlation spectroscopy. Eur. Biophys. J. (2002) 31:179-184.
116. WITTRUP KD: Protein engineering by cell-surface display. Curr. Opin. Biotechnol. (2001) 12:395-399. An excellent review on cell surface expression.
117. FELDHAUS MJ, SIEGEL RW, OPRESKO LK et al.: Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat. Biotechnol. (2003) 21:163-170.
118. CHANG Q, ZHONG Z, LEES A, PEKNA M, PIROFSKI L: Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci. Infect. Immun. (2002) 70:4977-4986.
119. KUROIWA Y, KASINATHAN P, CHOI YJ et al. Cloned transchromosomic calves producing human immunoglobulin. Nat. Biotechnol. (2002) 20:889-894.
120. ROBINSON WH, DIGENNARO C, HUEBER W et al.: Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat. Med. (2002) 8:295-301.
121. BLANK K, LINDNERP, DIEFENBACH B, PLUCKTHUN A: Self-immobilizing recombinant antibody fragments for immunoaffinity chromatography: generic, parallel, and scalable protein purification. Protein Expr. Purif. (2002) 24:313-322.
122. KAUFMANN M, LINDNER P, HONEGGER A, et al.: Crystal structure of the anti-His tag antibody 3D5 single-chain fragment complexed to its antigen. J. Mol. Biol. (2002) 318:135-147.
123. MURRAY A, MISSAILIDIS S, PRICE MR: Epitope affinity chromatography and biophysical studies of monoclonal antibodies and recombinant antibody fragment. J. Chromatogr. Sci. (2002) 40:343-349.
124. BAYLY AM, KORTT AA, HUDSON PJ, POWER BE: Large-scale bacterial fermentation and isolation of scFv multimers using a heat-inducible bacterial expression vector. J. Immunol. Methods (2002) 262:217-227.
125. DE GRAAF M, VAN DER MEULEN-MUILEMAN IH, PINEDO HM, HAISMA HJ: Expression of scFvs and scFv fusion proteins in eukaryotic cells. Methods Mol. Biol. (2002) 178:379-387.
126. VAQUERO C, SACK M, SCHUSTER F et al.: A carcinoembryonic antigen-specific diabody produced in tobacco. FASEB J. (2002) 16:408-410.
127. SWENNEN D, PAUL MF, VERNIS L, BECKERICH JM, FOURNIER A, GAILLARDIN C: Secretion of active anti-Ras single-chain Fv antibody by the yeasts Yarrowia lipolytica and Kluyveromyces lactis. Microbiology (2002) 148:41-50.
128. CHOO AB, DUNN RD, BROADY KW, RAISON RL: Soluble expression of a functional recombinant cytolytic immunotoxin in insect cells. Protein Expr. Purif. (2002) 24:338-347.
129. ARNDT KM, MULLER KM, PLUCKTHUN A: Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain. J. Mol. Biol. (2001) 312:221-228.
130. HONEGGER A, PLUCKTHUN A: The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains. J. Mol. Biol. (2001) 309:687-699.
131. HOYER W, RAMMA K, PLUCKTHUN A: A kinetic trap is an intrinsic feature in the folding pathway of single-chain Fv fragments. Biophys. Chem. (2002) 96:273-284.
132. SAPHIRE EO, STANFIELD RL, CRISPIN MD et al.: Contrasting IgG structures reveal extreme asymmetry and flexibility. J. Mol. Biol. (2002) 319:9-18.
133. DESMYTER A, DECANNIERE K, MUYLDERMANS S, WYNS L: Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J. Biol. Chem. (2001) 276:26285-26290.
134. EWERT S, CAMBILLAU C, CONRATH K, PLUCKTHUN A: Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. Biochemistry (2002) 41:3628-3636.
135. MURUGANANDAM A, TANHA J, NARANG S, STANIMIROVIC D: Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. (2002) 16:240-242.
136. VAN DEN BEUCKEN T, VAN NEER N, SABLON E et al.: Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J. Mol. Biol. (2001) 310:591-601.
137. MUYLDERMANS S: Single domain camel antibodies: current status. J. Biotechnol. (2001) 74:277-302.
138. IRVING RA, COIA G, ROBERTS A, NUTTALL SD, HUDSON PJ: Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics. J. Immunol. Methods (2001) 248:31-45.
139. LADNER RC, LEY AC: Novel frameworks as a source of high-affinity ligands. Curr. Opin. Biotechnol. (2001) 12:406-410.
140. SKERRA A: 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties. J. Biotechnol. (2001) 74:257-275.
141. KURTZMAN AL, GOVINDARAJAN S, VAHLE K, JONES JT, HEINRICHS V, PATTEN PA: Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins. Curr. Opin. Biotechnol. (2001) 12:361-370.
142. MARTINEAU P: Error-prone polymerase chain reaction for modification of scFvs. Methods Mol. Biol. (2002) 178:287-294.
143. IRVING RA, COIA G, RAICEVIC A, HUDSON PJ: Use of Escherichia coli mutator cells to mature antibodies. Methods Mol. Biol. (2002) 178:295-302.
144. LANTTO J, JIRHOLT P, BARRIOS Y, OHLIN M: Chain shuffling to modify properties of recombinant immunoglobulins. Methods Mol. Biol. (2002) 178:303-316.
145. CHAMES P, WILLEMSEN RA, ROJAS G et al.: TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J. Immunol. (2002) 169:1110-1118.
146. REITER Y: Recombinant immunotoxins in targeted cancer cell therapy. Adv. Cancer Res. (2001) 81:93-124.
147. SALVATORE G, BEERS R, MARGULIES I, KREITMAN RJ, PASTAN I: Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin. Cancer Res. (2002) 8:995-1002.
148. JUNG S, SPINELLI S, SCHIMMELE B et al.: The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subdassification of antibody V(H) domains. J. Mol. Biol. (2001) 309:701-716.
149. VEREL I, HEIDER KH, SIEGMUND M et al.: Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int. J. Cancer (2002) 99:396-402.
150. ADAMS GP, SCHIER R, MCCALL AM et al.: High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. (2001) 61:4750-4755. An important observation which suggests that high affinity can also be a limitation for tumour targeting and particularly for tumour penetration.